Treatment for Patients With Osteoarthritis (OA) of the Knee
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00110916 |
Recruitment Status
:
Completed
First Posted
: May 17, 2005
Last Update Posted
: February 22, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis | Drug: Intra-articular metHuIL-1ra (anakinra) Drug: placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 165 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Intra-Articular metHuIL-1ra (Anakinra) in Subjects With Osteoarthritis (OA) of the Knee |
Study Start Date : | June 2004 |
Actual Primary Completion Date : | February 2005 |
Actual Study Completion Date : | February 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: Anakinra
anakinra
|
Drug: Intra-articular metHuIL-1ra (anakinra)
anakinra
|
Placebo Comparator: placebo
placebo
|
Drug: placebo
placebo
|
- WOMAC [ Time Frame: 12 weeks ]
- Pain Patient's global assessment [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00110916
Study Director: | MD | Amgen |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Global Development Leader, Amgen Inc. |
ClinicalTrials.gov Identifier: | NCT00110916 History of Changes |
Other Study ID Numbers: |
20040100 |
First Posted: | May 17, 2005 Key Record Dates |
Last Update Posted: | February 22, 2008 |
Last Verified: | February 2008 |
Keywords provided by Amgen:
Intra-articular Osteoarthritis OA anakinra Amgen |
Additional relevant MeSH terms:
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases |
Rheumatic Diseases Interleukin 1 Receptor Antagonist Protein Antirheumatic Agents |